The company showed how they first defined A2A as the receptor required for mediating the effect of adenosine on immune cells within the tumor microenvironment and reported the characterization of
a novel immuno - oncology - dedicated adenosine receptor 2A antagonist that functions in the high adenosine concentration found in tumors.
FLX Bio, Inc. is a privately - held biopharmaceutical company focused on the discovery, development and commercialization of
novel immuno - oncology agents.
Not exact matches
A number of
immuno - oncology therapies on the horizon tackle this problem in
novel ways.
iTeos Therapeutics has developed a
novel and potent best - in - class A2A blocker that has been specifically optimized for
immuno - oncology indications to retain a high potency in the adenosine - rich environment found in tumors and to restore cytokine production even in the presence of high concentrations of adenosine.
iTeos has developed an innovative phenotypic screening platform that is applied to the identification of rational combinations for our current programs, and to the discovery of
novel targets for
immuno - oncology.
Genocea's pipeline includes GEN - 003, a
novel T cell - enabled immunotherapy for genital herpes currently in Phase 2 clinical development, and earlier - stage investments in
immuno - oncology.